Asset
OBRINDATAMAB
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03406949 | phase1 | completed | 2018-02-27 | 2022-04-27 | MacroGenics | MGD009/MGA012 Combination in Relapsed/Refractory Cancer |
| NCT02628535 | phase1 | terminated | 2015-09-01 | 2019-11-25 | MacroGenics | Safety Study of MGD009 in B7-H3-expressing Tumors |
FDA applications (0)
This company has no applications containing this asset.